GlassScriptPhysician profile
David P Buras
NPI 1245301373
$11,852.95
in general payments reported to CMS, 2019-2025
56 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $1,914 · 2021: $2,238 · 2022: $1,514 · 2023: $1,674 · 2024: $1,765 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,564 · Education: $40.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,564.31 |
| Education | $40.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,195.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,059.36 | 2019-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $879.72 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $746.26 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $655.27 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $576.23 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $529.84 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $423.95 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.99 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $353.10 | 2019-2020 | |
| Amarin Pharma, INC. | $341.88 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $265.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $186.53 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $164.65 | 2019-2023 | Livalo, Seglentis |
| Vanda Pharmaceuticals INC. | $160.85 | 2023-2024 | Hetlioz, Fanapt |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $135.04 | 2020-2024 | Eliquis |
| Lundbeck LLC | $126.52 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.23 | 2019-2021 | |
| Dexcom, INC. | $113.51 | 2019-2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $107.11 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $103.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $92.67 | 2020-2023 | Steglatro, Belsomra |
| Esperion Therapeutics, INC. | $79.46 | 2021-2024 | Nexletol |
| Sunovion Pharmaceuticals INC. | $78.81 | 2021 | |
| Hikma Pharmaceuticals USA | $76.26 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $71.97 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $65.22 | 2021-2023 | Trintellix |
| Abbott Laboratories | $58.26 | 2021 | |
| Sumitomo Pharma America, INC. | $55.72 | 2025 | Gemtesa |
| Itamar Medical INC | $55.61 | 2022 | |
| Genentech USA, INC. | $52.92 | 2019-2021 | |
| Tolmar, INC. | $43.70 | 2023-2025 | Jatenzo |
| Otsuka America Pharmaceutical, INC. | $33.12 | 2023 | Rexulti |
| Seqirus USA INC | $30.45 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $29.92 | 2023 | Contrave, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $29.31 | 2021 | |
| Eisai INC. | $27.92 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $27.49 | 2023 | Onpattro |
| Neuronetics, INC. | $25.41 | 2019 | |
| Phadia US INC. | $24.91 | 2024 | Immunocap |
| Mylan Specialty L.P. | $21.64 | 2022 | |
| Axsome Therapeutics, INC. | $21.44 | 2023 | Auvelity |
| Eyevance Pharmaceuticals LLC | $20.96 | 2021 | |
| Biogen, INC. | $19.33 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.55 | 2024 | Voquezna |
| Athena Bioscience, LLC | $17.00 | 2023 | Qdolo |
| Ibsa Pharma INC. | $16.24 | 2025 | Tirosint, Flector, Licart |
| Corcept Therapeutics | $15.66 | 2025 | Korlym |
| Acerus Pharmaceuticals Corporation | $15.28 | 2021 | |
| Medtronic, INC. | $14.54 | 2021 | |
| Verity Pharmaceuticals INC. | $13.71 | 2024 | Tlando |
| Amneal Pharmaceuticals LLC | $13.69 | 2025 | Unithroid |
| Philips North America LLC | $13.37 | 2020 | |
| Medtronic Minimed, INC. | $12.38 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.35 | 2020 | |
| Allergan, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Buras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.